Maintaining and optimising anti-TNF therapy.
Somerville
Margaret
M
Rheumatology Unit, Norfolk & Norwich University Hospital, Colney Lane, Norwich NR4 7UY, UK. margaret.somerville@nnuh.nhs.uk
D000465:Algorithms; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000191:economics / Q000627:therapeutic use; D000069285:Infliximab; D010818:Practice Patterns, Physicians'; D011364:Professional Practice; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012219:Rheumatology / Q000191:economics / Q000379:methods*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068800:Etanercept